References
- Hradsky O, Ohem J, Zarubova K, Mitrova K, Durilova M, Kotalova R, et al. disease activity is an important factor for indeterminate interferon-γ release assay results in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014;58:320–4.
- Mantzaris GJ, Tsironikos D, Tzanetakou X, Grispou E, Karatzas P, Kalogeropoulos I, et al. The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy. Scand J Gastroenterol 2015;50:1451–5.
- Bermejo F, Algaba A, Chaparro M, Taxonera C, Garrido E, García-Arata I, et al. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study. Dig Liver Dis 2013;45:733–7.
- Gisondi P, Pezzolo E, Lo Cascio G, Girolomoni G. Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. Br J Dermatol 2014;171:884–90.